Clinical Trials Logo

Tuberculous Pericarditis clinical trials

View clinical trials related to Tuberculous Pericarditis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04521803 Recruiting - Clinical trials for Tuberculous Pericarditis

High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis

IMPI-3
Start date: January 10, 2022
Phase: Phase 2
Study type: Interventional

The investigators hypothesise that high dose RIF (RIF35) will increase pericardial fluid RIF exposure and so enhance mycobacterial clearance, compared to standard of care dosing (RIF10). This Phase 2b randomized, placebo-controlled, double-blinded trial will evaluate the efficacy and safety of RIF 35mg/kg compared 10mg/kg, added to standard first-line ATT, for the treatment of PCTB.